|Bid||0.00 x 0|
|Ask||385.15 x 0|
|Day's Range||382.40 - 388.50|
|52 Week Range||362.00 - 558.50|
|PE Ratio (TTM)||25.10|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Zydus Wellness Limited (NSEI:ZYDUSWELL), a food company based in India, led the NSEI gainers with a relatively large price hike in the past couple of weeks. As a small capRead More...
With an ROE of 20.59%, Zydus Wellness Limited (NSEI:ZYDUSWELL) outpaced its own industry which delivered a less exciting 10.67% over the past year. On the surface, this looks fantastic sinceRead More...
Examining Cadila Healthcare Limited’s (NSEI:CADILAHC) past track record of performance is a valuable exercise for investors. It enables us to understand whether the company has met or exceed expectations, whichRead More...
Cadila Healthcare Limited (NSEI:CADILAHC) is trading with a trailing P/E of 32.1x, which is higher than the industry average of 29.5x. Although some investors may jump to the conclusion thatRead More...
Mid-caps stocks, like Cadila Healthcare Limited (NSEI:CADILAHC) with a market capitalization of ₹427.46B, aren’t the focus of most investors who prefer to direct their investments towards either large-cap or small-capRead More...
If the stock market is any guide, Sharvil Patel has just inherited one of the top generic drug manufacturers in the world. Now, he just has to figure out how to keep it that way.
India's drug pricing regulator has demanded explanations from 65 domestic and global drugmakers for selling new forms of essential diabetes and antibiotic drugs without its approval. The move could bring penalties for the drugmakers, among them Abbott Laboratories, Sanofi, Novartis and Indian firms such as Sun Pharmaceutical Industries and Lupin, the National Pharmaceutical Pricing Authority (NPPA) said on its website.